Goldman Sachs
BPMC

Goldman Sachs’s Blueprint Medicines BPMC Stock Holding History

Goldman Sachs’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,800
Closed -$996K – 5575
2023
Q4 		$996K Hold
10,800
– – ﹤0.01% 4388
2023
Q3 		$542K Hold
10,800
– – ﹤0.01% 4620
2023
Q2 		$683K Buy
10,800
+500
+5% +$27.2K ﹤0.01% 4568
2023
Q1 		$463K Buy
+10,300
New +$464K ﹤0.01% 4860
2020
Q3 		– Sell
-20,100
Closed -$1.57M – 5310
2020
Q2 		$1.57M Sell
20,100
-9,900
-33% -$670K ﹤0.01% 3627
2020
Q1 		$1.75M Sell
30,000
-600
-2% -$38.6K ﹤0.01% 3392
2019
Q4 		$2.45M Buy
+30,600
New +$2.29M ﹤0.01% 3502
2019
Q1 		– Sell
-30,000
Closed -$1.62M – 5143
2018
Q4 		$1.62M Buy
+30,000
New +$1.82M ﹤0.01% 3665
2017
Q3 		– Sell
-50,000
Closed -$2.53M – 6658
2017
Q2 		$2.53M Buy
+50,000
New +$2.12M ﹤0.01% 3642

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's BPMC Position: Q3 2025 in Review

Goldman Sachs sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 891,287 shares — an estimated $114M sold.

Goldman Sachs first reported a position in BPMC in Q2 2015 and held it in 40 quarters. The position peaked at $114M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Goldman Sachs reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 891,287 Blueprint Medicines shares in Q3 2025, an estimated $114M.
  • Goldman Sachs first reported a position in Blueprint Medicines in Q2 2015 and held it in 40 quarters.
  • Goldman Sachs's Blueprint Medicines position peaked at $114M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.